Peripheral and Central GLP-1 Receptor Populations Mediate the Anorectic Effects of Peripherally Administered GLP-1 Receptor Agonists, Liraglutide and Exendin-4
Open accessThe DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index.
Abstract
UNLABELLED: The long-acting glucagon-like peptide-1 receptor (GLP-1R) agonists, exendin-4 and liraglutide, suppress food intake and body weight. The mediating site(s) of action for the anorectic effects produced by peripheral administration of these GLP-1R agonists are not known. Experiments addressed whether food intake suppression after i.p. delivery of exendin-4 and liraglutide is mediated exclusively by peripheral GLP-1R or also involves direct central nervous system (CNS) GLP-1R activation. Results showed that CNS delivery [third intracerebroventricular (3(rd) ICV)] of the GLP-1R antagonist exendin-(9-39) (100 μg), attenuated the intake suppression by i.p. liraglutide (10 μg) and exendin-4 (3 μg), particularly at 6 h and 24 h. Control experiments show that these findings appear to be based neither on the GLP-1R antagonist acting as a nonspecific competing orexigenic signal nor on blockade of peripheral GLP-1R via efflux of exendin-(9-39) to the periphery. To assess the contribution of GLP-1R expressed on subdiaphragmatic vagal afferents to the anorectic effects of liraglutide and exendin-4, food intake was compared in rats with complete subdiaphragmatic vagal deafferentation and surgical controls after i.p. delivery of the agonists. Both liraglutide and exendin-4 suppressed food intake at 3 h, 6 h, and 24 h for controls; for subdiaphragmatic vagal deafferentation rats higher doses of the GLP-1R agonists were needed for significant food intake suppression, which was observed at 6 h and 24 h after liraglutide and at 24 h after exendin-4. CONCLUSION: Food intake suppression after peripheral administration of exendin-4 and liraglutide is mediated by activation of GLP-1R expressed on vagal afferents as well as direct CNS GLP-1R activation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“This is consistent with some prior studies demonstrating a role for NTS GLP-1R neurons in physiological satiation/satiety and for some of the anorectic effects of various GLP-1RAs, with some reporting an absence of evidence of proxies for nausea (109‐113).”
From GLP-1 and the Neurobiology of Eating Control: Recent Advances (2025) · cites this paper as [110]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Physiology of Glucagon-like Peptide 1
Holst, J. J. (2007) · Physiological Reviews · doi:10.1152/physrev.00034.2006 · Cited by 3,371 · cited 2×
“The long-acting GLP-1R agonists, exendin-4 and liraglutide, are efficacious in the treatment of T2DM and may hold promise for the treatment of obesity (5, 6, 28).”
BackgroundOgden, C. L., Yanovski, S. Z., Carroll, M. D., & Flegal, K. M. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.03.052 · Cited by 1,561
Astrup, A., Rössner, S., Van Gaal, L., Rissanen, A., Niskanen, L., Al Hakim, M., Madsen, J., Rasmussen, M. F., & Lean, M. E. (2009) · The Lancet · doi:10.1016/s0140-6736(09)61375-1 · Cited by 1,163
Abbott, C. R., Monteiro, M., Small, C. J., Sajedi, A., Smith, K. L., Parkinson, J. R. C., Ghatei, M. A., & Bloom, S. R. (2005) · Brain Research · doi:10.1016/j.brainres.2005.03.011 · Cited by 599 · cited 1×
“Similarly, others also show that ip administration of GLP-1 does not suppress short-term intake after total subdiaphragmatic vagotomy (12), and ip exendin-4 does not suppress intake up to 8 h after administration in capsaicintreated mice (50).”
BackgroundAgersø, H., Jensen, L. B., Elbrønd, B., Rolan, P., & Zdravkovic, M. (2002) · Diabetologia · doi:10.1007/s00125-001-0719-z · Cited by 510
Göke, R., Larsen, P. J., Mikkelsen, J. D., & Sheikh, S. P. (1995) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.1995.tb00650.x · Cited by 474
Vilsbøll, T., Zdravkovic, M., Le-Thi, T., Krarup, T., Schmitz, O., Courrèges, J.-P., Verhoeven, R., Bugánová, I., & Madsbad, S. (2007) · Diabetes Care · doi:10.2337/dc06-2593 · Cited by 468
Glucoreceptors Controlling Feeding and Blood Glucose: Location in the Hindbrain
Ritter, R. C., Slusser, P. G., & Stone, S. (1981) · Science · doi:10.1126/science.6264602 · Cited by 467 · cited 1×
“After a 7-d surgical recovery period, 3 ICV cannula placement was assessed by measurement of the sympathoadrenal-mediated hyperglycemic response to the cytoglucopenia induced by 5-thio-D-glucose (210 g in 2 l aCSF) (20).”
MethodGlucagon-like peptide-1 inhibits gastric emptying via vagal afferent-mediated central mechanisms
I˙meryüz, N., Yeğen, B. Ç., Bozkurt, A., Coşkun, T., Villanueva-Peñacarrillo, M. L., & Ulusoy, N. B. (1997) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.1997.273.4.g920 · Cited by 432
Blonde, L., Klein, E. J., Han, J., Zhang, B., Mac, S. M., Poon, T. H., Taylor, K. L., Trautmann, M. E., Kim, D. D., & Kendall, D. M. (2006) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2006.00602.x · Cited by 416
Cited by
Items 301–345 of 345
Neuropeptides and the Autonomic Nervous System in Prader–Willi Syndrome
Höybye, C., & Petersson, M. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms27010352 · Cited by 4
“GLP-1 exerts its central effects through the GLP-1 receptor in the central nervous system, reducing the rate of absorption of food into the blood via appetite suppression and delayed gastric emptying [71–73].”
GLP-1 and Parkinson’s Disease: A Comprehensive Review of Biology, Mechanisms and Efficacy
Mezabrovschi, R., Gegg, M. E., & Schapira, A. H. V. (2026) · Cells · doi:10.3390/cells15090804 · Cited by 3
“In contrast, the humoral pathway—the direct entry of GLP-1 into the brain across the BBB—is thought to play a more limited role due to rapid peripheral degradation [64].”
Bashaw, A. G., Roman-Ortiz, C., Gao, S. X., Schier, L. A., Borner, T., & Kanoski, S. E. (2026) · Biological Psychiatry · doi:10.1016/j.biopsych.2026.06.006 · Cited by 5
Self-citationRegulation of Appetite and Satiety by Gastrointestinal Peptides
Mhaibes, S. H., Fakree, N. K., & Naser, S. E. (2021) · Iraqi Journal of Pharmaceutical Sciences · doi:10.31351/vol30iss1pp14-21 · Cited by 4
A New Epoch in Treating Diseases of the Heart
Purnell, J. Q., & Camacho, S. A. (2024) · Journal of clinical lipidology · doi:10.1016/j.jacl.2024.01.007 · Cited by 2
Glucagon-like peptide-1 receptor
Krashes, M. J. (2024) · Current Biology · doi:10.1016/j.cub.2024.10.039 · Cited by 2
Applebey, S. V., Xiao, A. G., Reiner, B. C., & Hayes, M. R. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70177 · Cited by 2
“9,19,47 Moreover, fluorescently-labelled semaglutide and liraglutide reach and provoke increased neuronal activity in the Arc, PVN, NTS/AP, and increase neuronal activity in the BNST and CeA.”
Self-citationUnderstanding the Effects of Roux-en-Y Gastric Bypass (RYGB) Surgery on Type 2 Diabetes Mellitus
Raymond, G. S., Radin, M. S., Collin, E., & Ragoli, L. (2013) · InTech eBooks · doi:10.5772/56398 · Cited by 3
Metabolic Effects of Bariatric Surgery: A Focus on Inflammation and Diabetic Kidney Disease
Neff, K., & le Roux, C. W. (2013) · Current Obesity Reports · doi:10.1007/s13679-013-0050-2 · Cited by 3
CCK Response Deficiency in Synphilin-1 Transgenic Mice
Smith, W. W., Smith, M., Yang, D., Choi, P. P., Moghadam, A. A., Li, T., & Moran, T. H. (2015) · PLoS ONE · doi:10.1371/journal.pone.0142314 · Cited by 2
Pharmacotherapy for Weight Loss
Lutz, T. A., & Asarian, L. (2017) · CRC Press eBooks · doi:10.1201/9781315120171-13 · Cited by 3
Insights into the mechanisms of body weight control
Pereira, S. (2025) · AJP Advances in Physiology Education · doi:10.1152/advan.00091.2025 · Cited by 1
The central amygdala gates exogenous glucagon-like peptide 1 signals
Duran, M., Zeng, N., Cutts, E. J., POLAMARASETTY, A., Rodríguez, M., Habegger, K. M., & Hardaway, J. A. (2026) · Molecular Metabolism · doi:10.1016/j.molmet.2026.102403 · Cited by 2
“GLP-1R-expressing cells are evolutionarily conserved and enriched in brain nuclei that respond to exogenous GLP-1R agonists [8 — 10, 30, 37, 58 — 62].”
Rodríguez-Flores, M., & Stephano, S. (2024) · Advances in neurobiology · doi:10.1007/978-3-031-45493-6_18 · Cited by 1
The Gastrointestinal System and Obesity
Calderón, G., & Acosta, A. J. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-814468-8.00004-1 · Cited by 3
The Effect of Glucagon-like Peptide-1 (GLP-1) on Obesity
Huang, X., Liang, M., & Wei, B. (2019) · Critical Care Obstetrics and Gynecology · doi:10.21767/2471-9803.1000171 · Cited by 1
Pacheco‐López, G., & Langhans, W. (2013) · Elsevier eBooks · doi:10.1016/b978-0-12-385095-9.00149-4 · Cited by 3
Lopez, C., Duran, M., VIRKUS, S., Yadav, E., MCMICHEN, K. A., Singh, J. A., Ramsey, V. A., Stocking, S. Q., Habegger, K. M., & Hardaway, J. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.05.11.540425 · Cited by 1
“Group (ChrimsonR/TdTomato) X Laser/Epoch effect: F (1, 8) = 1.”
A review of a self-prescribed medication regime in undiagnosed diabetes
Sheridan, S. (2015) · Journal of Paramedic Practice · doi:10.12968/jpar.2015.7.7.350
Mietlicki‐Baase, E. G., & Hayes, M. R. (2015) · Springer eBooks · doi:10.1007/978-3-319-12125-3_25-1 · Cited by 2
Self-citationThe Role of Efferent Cholinergic Transmission for the Insulinotropic and
Plamboeck, A., Veedfald, S., Deacon, C. F., Hartmann, B., Tina, T., Knop, F. K., & Holst, J. J. (2015)
Moran, T. H., & Sakai, R. R. (2012) · Wiley eBooks · doi:10.1002/9781118133880.hop203011
Farr, S. (2017) · TSpace (University of Toronto)
Pharmacological Evaluation of GPR40 Full Agonists in Metabolic Disease Models
上野, 光., ウエノ, ヒ., & Ueno, H. (2021) · Terrestrial Environment Research Center (University of Tsukuba)
Mietlicki‐Baase, E. G., & Hayes, M. R. (2016) · Springer eBooks · doi:10.1007/978-3-319-11251-0_25
Self-citationEfeito do sistema incretínico sobre o recrutamento de adipócitos bege
Oliveira, F. C. B. (2018) · RIUnB Institutional Repository (University of Brasília) · doi:10.26512/2018.02.t.32242
Rosenzweig, S. A. (2020) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.727123638.793572332
Pharmacotherapy for Weight Loss
Lutz, T. A., & Asarian, L. (2017) · Routledge eBooks · doi:10.1201/9781315120171-14 · Cited by 1
Abshire, K. M., & Leggio, L. (2023) · Elsevier eBooks · doi:10.1016/b978-0-12-823453-2.00013-8
Glucagon-like peptide-1 receptor agonists and derivatives in the treatment of obesity - review
Rabenda, M., Słomczyński, A., Zatyka, P., Pawłowska, A., Opala, D., Osuch, D., & Janik, P. E. (2024) · Quality in Sport · doi:10.12775/qs.2024.20.53995 · Cited by 1
Challenges and Novelties in the Treatment of Obesity in Adults. A review
Kuczapska, K., Kurowski, M., Gliwa, A., Ryglewicz, M., Fabian, D., Leszczyńska-Knaga, E., Jakubczyk, N., Rutkowska-Kawalec, W., Moczydłowski, P., & Michalczuk, K. (2025) · Journal of Education Health and Sport · doi:10.12775/jehs.2025.77.57095
Alhamedi, N. M. (2025) · Journal of Clinical Medical Research · doi:10.46889/jcmr.2025.6104 · Cited by 1
Bremmer, M. P., Courtney, J. B., Neilson, A. P., Burger, K. S., Thiele, T. E., & Hendershot, C. S. (2025) · Psychopharmacology · doi:10.1007/s00213-025-06980-y
Khlaifia, A. (2015) · theses.fr (ABES) · doi:10.70675/48826ff3zef5bz49d0z8389z57ab7666f35b
Galmiche, M. C. (2019) · theses.fr (ABES) · doi:10.70675/86478abdzfb8bz4442z8e08z65e991beb2b0 · Cited by 1
The central amygdala integrates exogenous glucagon-like peptide 1 signalsPreprint
Duran, M., Zeng, N., Cutts, E. J., Habegger, K. M., & Hardaway, J. A. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.04.06.716705
Tudosie, A. C., Marin, L.-M., Popa, S. G., & Golli, A. L. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27083628 · Cited by 2
Regulators of appetite in mammals—old and new players
Fernandes, J. H., Silva, J. D., Costa, M. D., & Maciel, P. (2026) · Endocrine Reviews · doi:10.1210/endrev/bnag020 · Cited by 1
Lebertová, L., Marková, I., Hüttl, M., Černá, K., Zapletalová, I., & Malínská, H. (2026) · Antioxidants · doi:10.3390/antiox15060729
Brain-Wide Connectivity of GLP1R Neurons in the Thalamic Reticular Nucleus
Zhang, X., Zhu, S., Lan, J., Duan, S., Han, Y., & Shi, P. (2026) · Journal of Integrative Neuroscience · doi:10.31083/jin52117
Kurowski, M., Rekiel, K., Marcinkowska, A., Ratajczyk, O., Urbanowicz, P., Iwankiewicz, S., Grzelczak, W., & mierczak, Z. K. (2026) · Medical Journal of Cell Biology · doi:10.2478/acb-2026-0005
A clinical and experimental investigation of liraglutide effects on the brain-kidney axis
Greenwood, M. P., Alotaibi, M. I., Bárez‐López, S., Cantley, N. W. P., Merritt, S., Tatović, D., & Murphy, D. (2026) · Science Advances · doi:10.1126/sciadv.aef4951
Metadata
- Authors
- Kanoski, S. E., Fortin, S. M., Arnold, M., Grill, H. J., & Hayes, M. R.
- Affiliations
- University of Pennsylvania (US)
- ETH Zurich (CH)
- Corresponding author
- Kanoski, Scott E.
- Venue
- Endocrinology
- Publisher
- The Endocrine Society
- Published
- 2011-06-21
- Volume
- 152
- Issue
- 8
- Pages
- 3103-3112
- ISSN
- 0013-7227 (ISSN-L)
- 1945-7170
- PMC
- PMC3138234
- OpenAlex
- W1965072462
- Cited by
- 347
- References
- 51
- Citations by year
- 2026: 16 · 2025: 26 · 2024: 21 · 2023: 16 · 2022: 18 · 2021: 30 · 2020: 23 · 2019: 26 · 2018: 19 · 2017: 21 · 2016: 27 · 2015: 24 · 2014: 22 · 2013: 25 · 2012: 23
- FWCI
- 11.85
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Endocrinology (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- University of Pennsylvania
- National Institutes of Health (DK21397, DK089752)
- National Institute of Diabetes and Digestive and Kidney Diseases (DK089752, DK085435, R01DK021397, F32DK089752, K01DK085435, DK 21397, R56DK021397)
- Topics
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Keywords
- GLP-1 receptor agonists, liraglutide, exendin-4, exendin-9-39, feeding inhibition, anorectic effect, vagal afferents, intracerebroventricular administration, appetite regulation
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Liraglutide, Exenatide, Animals, Appetite Depressants, Body Weight, Brain, Calcitonin, Eating, Male, Peptide Fragments, Peptides, Vagus Nerve, Venoms, Rats, Sprague-Dawley, Receptors, Glucagon, Rats, Glucagon-Like Peptide 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.